Financial Performance - Q2 2025 revenue reached $106 million[11] - The company reported an operating loss of $1.1 million[15] - Earnings per share stood at $0.22[19] - Revenue per active earning coach (AEC) was $4,630[13, 14] - As of June 30, 2025, cash and investments totaled $163 million[6, 21, 22] Coach Network and Productivity - The company has 22,800 active earning coaches[20] - Revenue per active earning coach declined 6.9% year-over-year but increased sequentially for the second consecutive quarter[8] - New coach productivity exceeded the same period last year[8] - 60% of coaches have had at least one client on GLP-1 medications[30, 70] Strategic Initiatives - The company is focusing on science-driven innovation and offer evolution[23, 65] - The Premier+ program streamlines pricing and processes to improve retention and aid recruitment[25, 48, 51] - The OPTAVIA EDGE program is designed to drive coach productivity, client acquisition, and leadership development[52, 71] Market and Health Focus - The company is addressing the rising metabolic health challenge, with 9 out of 10 U S adults being metabolically unhealthy[31, 69] - The OPTAVIA 5&1 Plan has been shown to impact key drivers of metabolic health, retaining 98% of lean mass in a clinical trial[38, 40] Q3 2025 Guidance - The company projects Q3 2025 revenue between $70 million and $90 million[75] - Q3 2025 loss/earnings per share is expected to be between ($0.60) and $0.00[75]

Financial Performance - Q1 2025 revenue reached $116 million[11] - Revenue per active earning coach (AEC) declined by 1.4% year-over-year[8] - The company reported an operating loss of $1.3 million[15] and a loss per share of $0.07[18] - Gross profit margin remained unchanged at 72.8% compared to Q1 2024[5] - The company is debt-free with $165 million in cash and investments as of March 31, 2025[6, 22] Coach and Customer Trends - The number of active earning coaches was 25,400[20] - New coaches grew by double digits year-over-year, marking the highest growth in 3 years[8] - New coach productivity exceeded the same period last year[8] - Almost 50% of coaches have had at least one customer on GLP-1 medications[69] Strategic Initiatives and Future Outlook - The company is targeting $15 million to $20 million in additional savings in 2025[78, 83] - Q2 2025 revenue is projected to be between $85 million and $105 million[90] - Q2 2025 earnings per share are expected to range from a loss of $0.55 to $0.00[90] - The company is expanding its focus to cater to customers in various need-states, including those using GLP-1 medications[24, 31]